Division of Hematology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Division of Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
JCO Oncol Pract. 2021 Feb;17(2):e119-e129. doi: 10.1200/OP.20.00517. Epub 2021 Jan 14.
Prior studies show that many patients receiving palliative cancer therapies misperceive likelihood of cure. Patients' understanding of treatment benefits and risks beyond cure is unknown. We explore patient perceptions of palliative treatment in the novel therapeutic era.
We surveyed patients with advanced solid cancers and their oncologists regarding benefits and risks of palliative therapies. We assessed perceived likelihood of tumor response, survival benefit, symptom palliation, and side effects. We used generalized estimating equations to calculate least squares means of misperception (patient-assessed minus physician-assessed likelihood of benefit), accounting for clustering by physician, and compared the degree of misperception by participant characteristics.
Of the 119 patients enrolled, median age was 65 years (range, 59-73 years), 55% were male, and 56% had prior treatment. Treatments included chemotherapy (60%), immunotherapy (24%), and targeted therapy (15%). Compared with their oncologists, patients overestimate curability (median misperception, 20%; interquartile range [IQR], 0 to 60), chances of tumor response (median, 20%; IQR, 0 to 40), symptom palliation (median, 10%; IQR, -10 to 30), and survival benefit (median, 20%; IQR, 0 to 40). Toxicity was relatively accurately estimated (median, 0.5%; IQR, -20 to 20). Immunotherapy was associated with higher risk of misperception of tumor response and toxicity. Misperceptions of tumor response and curability did not correlate (r = 0.13, = .15).
Compared with their oncologists, patients overestimated chances of tumor response, symptom palliation, and survival benefit, but accurately perceived likelihood of toxicity. There was no strong correlation between perception of curability and other goals of therapy. Communication focused on treatment goals alongside risks may reduce misperceptions and facilitate informed choices by patients.
先前的研究表明,许多接受姑息性癌症治疗的患者对治愈的可能性存在误解。患者对治愈以外的治疗益处和风险的理解尚不清楚。我们探讨了在新的治疗时代患者对姑息性治疗的看法。
我们调查了患有晚期实体瘤的患者及其肿瘤医生对姑息性治疗的益处和风险的看法。我们评估了患者对肿瘤反应、生存获益、症状缓解和副作用的可能性的看法。我们使用广义估计方程计算了感知偏差的最小二乘均值(患者评估的益处可能性减去医生评估的益处可能性),考虑了医生聚类,并根据参与者特征比较了感知偏差的程度。
在纳入的 119 名患者中,中位年龄为 65 岁(范围,59-73 岁),55%为男性,56%有既往治疗史。治疗包括化疗(60%)、免疫治疗(24%)和靶向治疗(15%)。与他们的肿瘤医生相比,患者高估了可治愈性(中位数感知偏差为 20%,四分位距[IQR]为 0 至 60)、肿瘤反应的可能性(中位数为 20%,IQR 为 0 至 40)、症状缓解的可能性(中位数为 10%,IQR 为-10 至 30)和生存获益的可能性(中位数为 20%,IQR 为 0 至 40)。毒性相对准确地估计(中位数为 0.5%,IQR 为-20 至 20)。免疫治疗与肿瘤反应和毒性的感知偏差风险较高相关。肿瘤反应和可治愈性的感知偏差没有相关性(r = 0.13,p = 0.15)。
与他们的肿瘤医生相比,患者高估了肿瘤反应、症状缓解和生存获益的可能性,但准确地感知了毒性的可能性。对可治愈性的感知与治疗的其他目标之间没有很强的相关性。将治疗目标与风险结合起来进行沟通,可能会减少误解,并促进患者做出知情选择。